ReviewFrontiers in bioengineering and biotechnology2023
Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.
Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Research advances in aptamers in the diagnosis and treatment of breast cancer (Review).International journal of oncology · 2026Review
- Review
- Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation.Advanced drug delivery reviews · 2025Review
- Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers · 2025Review
- Diagnostic methods for pancreatic cancer and their clinical applications (Review).Oncology letters · 2025Review
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Nanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications.International journal of nanomedicine · 2025Review
- Aptasensor based on cascaded fluorescent sensor assisted by exonuclease III for ultra-sensitive detection of HgAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Article
- Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications.Journal, genetic engineering & biotechnology · 2024Review
- Aptamers for the Delivery of Plant-Based Compounds: A Review.Pharmaceutics · 2024Review
- Aptamer-engineered (nano)materials for theranostic applications.Theranostics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a major cause of human death all over the world. Traditional cancer treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and hormone therapy. Although these conventional treatment methods improve the overall survival rate, there are some problems, such as easy recurrence, poor treatment, and great side effects. Targeted therapy of tumors is a hot research topic at present. Nanomaterials are essential carriers of targeted drug delivery, and nucleic acid aptamers have become one of the most important targets for targeted tumor therapy because of their high stability, high affinity, and high selectivity. At present, aptamer-functionalized nanomaterials (AFNs), which combine the unique selective recognition characteristics of aptamers with the high-loading performance of nanomaterials, have been widely studied in the field of targeted tumor therapy. Based on the reported application of AFNs in the biomedical field, we introduce the characteristics of aptamer and nanomaterials, and the advantages of AFNs first. Then introduce the conventional treatment methods for glioma, oral cancer, lung cancer, breast cancer, liver cancer, colon cancer, pancreatic cancer, ovarian cancer, and prostate cancer, and the application of AFNs in targeted therapy of these tumors. Finally, we discuss the progress and challenges of AFNs in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.